REGULATORY

• 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
  April 14, 2021

• Novo’s Growth Hormone, Fujimoto’s Hemophilia Med Skip April Listing
  April 14, 2021

• Japan to Prioritize Screening for N501Y Variant; E484K “Does Not Render Vaccines Ineffective”: Minister
  April 14, 2021

• LDP Pharma Study Group to Discuss R&D Support, Eyes Proposal
  April 13, 2021

• Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
  April 13, 2021

• COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
  April 12, 2021

• Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
  April 12, 2021

• Development of Japan-Made Vaccines “Significantly Meaningful”: Minister
  April 12, 2021

• MSD’s Recarbrio Up for PAFSC Review on April 21
  April 8, 2021

• Label Update Will Suffice to Expand COVID-19 Vaccination Age: MHLW Official
  April 7, 2021

• AMED to Set Up Council to Hone Academic Seeds with Industry Input
  April 7, 2021

• MHLW Launches New Office to Fuel SaMD Commercialization
  April 6, 2021

• MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
  April 6, 2021

• Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
  April 6, 2021

• 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
  April 5, 2021

• Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
  April 5, 2021

• Japan Mulls Expanding COVID-19 Vaccination Age to 12-15
  April 5, 2021

• MHLW Calls for Thiola’s Priority Use for Cystinuria as Shortage Expected
  April 2, 2021

• Neurosurgical Expert Eager to Carry Out Bridging Study of Cannabis-Derived Drug in Japan
  April 2, 2021

• Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
  April 1, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 150
• 151
• 152
• 153
• 154
• 155
• 156
• 157
• 158
• …
• Next ›
• 最終 »